COMPLETE                                  SCIENTIFIC Program                                       SCHEDULE &             ...
Dear Mental Health Practitioner:      I’ve been involved in both clinical and academic psychiatry for many years, and     ...
General Schedule                  Thursday, November 8	 7:30 a.m.–8:00 a.m.	      Welcome	 8:00 a.m.–8:30 a.m.	      Break...
®       ®        2012 Psych Congress Faculty     2012 Psych Congress Steering Committee                                   ...
2012 Psych Congress Faculty                                                                                               ...
®        ®    Scientific Program	                                                                                     SCIE...
Scientific Program	                                                              Thursday, november 8, 2012               ...
®      ®        Scientific Program	                                                                    Thursday, november ...
Scientific Program	                                                               Thursday, november 8, 2012              ...
®       ®         Scientific Program	                                                                        Friday, novem...
Scientific Program	                                                                        Friday, november 9, 2012       ...
®       ®         Scientific Program	                                                                    Friday, november ...
Scientific Program		                                                                  Friday, november 9, 2012            ...
®       ®       SCIENTIFIC PROGRAM	                                                            Saturday, november 10, 2012...
SCIENTIFIC PROGRAM	                                                              Saturday, november 10, 2012              ...
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
25th Annual U.S. Psychiatric and Mental Health Congress
Upcoming SlideShare
Loading in …5

25th Annual U.S. Psychiatric and Mental Health Congress


Published on

1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

25th Annual U.S. Psychiatric and Mental Health Congress

  1. 1. COMPLETE SCIENTIFIC Program SCHEDULE & PROGRAM ®Choose from more than 80 exciting sessions • Interact with over 85 exhibitorsnovember 8-11, 2012 • San diego Convention CenterRegister before October 5th for only $699! call: 800-237-7285 ext. 233 or visit
  2. 2. Dear Mental Health Practitioner: I’ve been involved in both clinical and academic psychiatry for many years, and ® ® this experience has really brought home to me how unique and valuable the U.S. Psychiatric and Mental Health Congress truly is. As I think about academic meetings, a lot of data are presented and often the information is only tangentially relevant to the practicing clinician. Celebrating 25 Years of Optimal Education For Mental Health Professionals What makes Psych Congress so unique is that it manages to bring cutting-edge science together in ways that have immediate clinical implications. Psych Congress speakers do a fantastic job of not just reporting facts and figures, but of synthesiz- ing these data to tell a larger story. Sometimes the story is practical and immediately Table Of Contents relevant; other times, the story is more abstract and inspiring for future directions of mental health care. 4 Steering Commitee and Faculty 6 Scientific Program For the practicing mental health practitioner, there is nothing like Psych Congress. I 20 Education Annex know of no other event that provides so broad a range of teaching on topics central 21 Exhibitors to our work and improving patient outcomes. 22 Hotel and Travel 23 Registration As the program chair of this 25th annual meeting, I invite you to join us to see for yourself how impactful this event is. I look forward to seeing you in San Diego! Logistic and meeting provider sponsor and education provider , LLC TM Respectfully, HMP Communications, LLC CME LLC/NACCME 83 General Warren Blvd., Suite 100 300 Rike Drive, Suite A Malvern, PA 19355 Millstone Township, NJ 08535 Charles Raison, MD Toll-free: 800-237-7285 Phone: 609-371-1137 Phone: 610-560-0500 Fax: 609-371-2733 2012 Psych Congress Program Chair Fax: 610-560-0502 www.hmpcommunications.com22 Register Today: Please visit Register early and save Register early and save at
  3. 3. General Schedule Thursday, November 8 7:30 a.m.–8:00 a.m. Welcome 8:00 a.m.–8:30 a.m. Breakfast 8:30 a.m.–11:45 a.m. Educational Sessions 11:45 a.m.–12:30 p.m. Lunch Break 12:00 p.m.–1:30 p.m. Lunch Professional Medical Education Presentation 12:30 p.m.–7:15 p.m. Educational Sessions 7:30 p.m.–8:30 p.m. Restoring Balance Workshops Friday, November 9 8:00 a.m.–8:30 a.m. Breakfast 8:30 a.m.–9:30 a.m. Breakfast Professional Medical Education Presentation 8:30 a.m.–11:45 a.m. Educational Sessions 11:00 a.m.– 4:00 p.m. Exhibit Hall and Education Annex 12:00 p.m.–12:30 p.m. Lunch Break12:00 p.m.–1:30 p.m. Lunch Professional Medical Education Presentation 12:30 p.m.–2:00 p.m. Educational Sessions 2:00 p.m.–4:00 p.m. Exhibit Hall and Education Annex Who Should Attend? 4:00 p.m.–7:15 p.m. Educational Sessions Psych Congress is designed for psychiatrists, primary care physicians, psychiatric nurses, phy- Earn Up To 30 7:30 p.m.–8:30 p.m. Restoring Balance Workshops Saturday, November 10 sician assistants, psychologists, and other health care professionals who seek to improve their 8:00 a.m.–8:30 a.m. Breakfast care for patients with mental health disorders and the outcomes resulting from that care. 8:30 a.m.–9:30 a.m. Breakfast Professional Medical Education Presentation Instructional level: Intermediate CME/CE Credits 8:30 a.m.–11:45 a.m. Educational Sessions 11:00 a.m.–4:00 p.m. Exhibit Hall and Education Annex 12:00 p.m.–12:30 p.m. Lunch Break Learning Objectives12:00 p.m.–1:30 p.m. Lunch Professional Medical After completing this educational program, participants should be able to do the following: Education Presentation 12:30 p.m.–2:00 p.m. Educational Sessions 1. Identify the etiology, pathophysiology, and neural pathways of various psychiatric disorders and their effects on patients. 2:00 p.m.–4:00 p.m. Exhibit Hall and Education Annex 4:00 p.m.–7:15 p.m. Educational Sessions 2. Increase ability to assess psychiatric disorders as well as patients’ overall health, including comorbidities, with the 7:30 p.m.–8:30 p.m. Restoring Balance Workshops goal of improving diagnosis and treatment. Sunday, November 11 3. Implement evidence-based models on the use of psychotherapeutic and pharmacotherapeutic interventions to 8:00 a.m.–8:30 a.m. Breakfast develop treatment plans, predict treatment response, optimize remission, and prevent relapse. 8:30 a.m.–11:45 a.m. Educational Sessions 12:00 p.m.–12:30 p.m. Lunch Break 4. Employ strategies to identify and remove barriers to treatment in order to improve patient outcomes in the acute 12:30 p.m.–3:45 p.m. Educational Sessions and long-term management of psychiatric disorders.Register Today: call 800-237-7285, ext. 233 Register early and save 3
  4. 4. ® ® 2012 Psych Congress Faculty 2012 Psych Congress Steering Committee Marc E. Agronin, MD Medical Director for Mental Health and Clinical Research, Miami Jewish Health Systems, Miami, FL; Affiliate Associate Professor of Psychiatry and Neurology, University of Miami Miller School of CME LLC is partnering with six respected minds in the fields of psychiatry and psychology to make 2012 Medicine, Miami, FL Psych Congress a practical and relevant educational experience. Lori R. Daniels, PhD Vet Center/Readjustment Counseling Services, Department of Veterans Affairs, Portland, OR Charles Raison, MD 2012 Psych Congress Program chair Karl Doghramji, MD Professor of Psychiatry, Neurology, and Medicine, Associate Professor, Department of Psychiatry, University of Arizona College of Medicine; Barry Medical Director, Jefferson Sleep Disorders Center, Thomas Jefferson and Janet Lang Associate Professor, John & Doris Norton School of Family and Consumer Sciences, University, Philadelphia, PA University of Arizona, Tucson, AZ; Mental Health Expert/Mind-Body Consultant,; Scientific President, European Association of Clinical Psychoneuroimmunology Craig L. Donnelly, MD Professor of Psychiatry and Pediatrics, Dartmouth Medical School, Hanover, NH; Chief, Section of Child and Adolescent Psychiatry, Dartmouth-Hitchcock Medical Center, Department of Psychiatry, ADVISORY BOARD Lebanon, NH Rakesh Jain, MD, MPH Vladimir Maletic, MD, MS M. Carmela Epright, PhD Associate Professor, Philosophy, Furman Director of Psychiatric Drug Research R/D Clinical Professor of Neuropsychiatry and University, Greenville, SC; Ethics Consultant, The Medical University of South Clinical Research Center, Lake Jackson, TX; Behavioral Science, University of South Carolina, Charleston, SC; Ethics Consultant, Greenville Hospital System, Associate Clinical Professor, Department Carolina School of Medicine, Columbia, SC; Greenville, SC of Psychiatry and Behavioral Sciences, Uni- Consulting Associate, Division of Child and versity of Texas Medical School at Houston, Adolescent Psychiatry, Department of Gregory Franchini, MD Director, Wellness Program, University of New Houston, TX Psychiatry, Duke University, Durham, NC Mexico School of Medicine, Albuquerque, NM Saundra Jain, PsyD, MBA, LPC Jon W. Draud, MS, MD Noel C Gardner, MD, MDiv Adjunct Professor, University of Utah, Salt Lake City, UT Executive Director, Mental Aerobics Project, CME LLC PSYCHIATRY Lake Jackson, TX CLINICAL DIRECTOR Almari Ginory, DO Forensic Fellow, University of Florida, Gainesville, FL; Clinical Professor of Psychiatry, University of Assistant Professor, University of Florida, Gainesville, FL Tennessee College of Medicine, Memphis, TN; Medical Director of Psychiatry, Addiction Ian H. Gotlib, PhD David Starr Jordan Professor of Psychology, Stanford Andrew Penn, RN, MS, NP, CNS, APRN-BC Medicine Services; Baptist Hospital, Nash- University, Stanford, CA Psychiatric Nurse Practitioner Kaiser Perman- ville, TN; Middle Tennessee Medical Center, ente. Redwood City, CA; Assistant Clinical Pro- Murfreesboro, TN; Private Practice, Adult and Kevin Gray, MD Associate Professor, Departments of Psychiatry and fessor, University of California, San Francisco, Adolescent Psychiatry Neurology, University of Texas Southwestern Medical Center, Dallas, TX San Francisco, CA4 Register Today: Register early and save
  5. 5. 2012 Psych Congress Faculty ® ®Doris Greenberg, MD Developmental and Behavioral Pediatrician Laura M. Mayol Sabatier, MD Child and Adolescent Fellow, University of Gerard Sanacora, MD, PhD Professor, Yale University, School ofand Associate Clinical Professor of Pediatrics, Mercer University School Florida, Gainesville, FL Medicine, New Haven, CTof Medicine, Savannah, GA; Director of Behavioral and Developmental Bill McCarberg, MD Founder, Chronic Pain Management Program, Kaiser David J. Scheiderer, MD, MBA, DFAPA Director of Education, IntegrativePediatric Rotation, Residency in Pediatrics, Memorial University Medical Permanente, San Diego, CA; Adjunct Assisting Clinical Professor, University Psychiatry, Inc., Sarasota, FL; Preisdent, Tiberius Enterprises, Roanoke, VACenter, Savannah, GA; Board Certified in Pediatrics and Developmental and of California, San Diego, CABehavioral Pediatrics Charles Schulz, MD Professor and Head, University of Minnesota, Laura J. Miller, MD Vice Chair for Academic Clinical Services, Minneapolis, MNJudith Grisel, PhD Professor and Chair, Department of Neuroscience, Department of Psychiatry, Brigham and Women’s Hospital, Boston, Kenneth J. Shapiro, PhD Executive Director, Animals and SocietyFurman University, Greenville, South Carolina MA; Professor, Harvard Medical School, Boston, MA; Director, Women’s Institute, Ann Arbor, MIRobert L. Hendren, DO Professor and Vice Chair, University of California, Mental Health Division, Department of Psychiatry, Brigham and Women’sSan Francisco, San Francisco, CA Hospital, Boston, MA David Sheehan, MD, MBA Distinguished University Health Professor Emeritus; University of South Florida College of Medicine; Tampa, FLIsrael C. Kalman, MS Director, Bullies to Buddies, Inc., Staten Island, NY; Michael C. Mithoefer, MD Private Practice of Psychiatry and ClinicalSpeaker, Cross Country Education, Nashville, TN Research, MAPS, Mount Pleasant, SC; Clinical Assistant Professor, Stephen V. Sobel, MD Clinical Instructor, University of California, San Diego, Department of Psychiatry and Behavioral Sciences, Medical University of School of Medicine, San Diego, CA; Consulting Psychiatrist, NFL San Diego Chargers,Walter H. Kaye, MD Professor of Psychiatry, University of California, San Diego, CA; Consulting Psychiatrist, MLB San Diego Padres, San Diego, CA South Carolina, Charleston, SCSan Diego, San Diego, CA; Program Director, Eating Disorders Program,University of California, San Diego, San Diego, CA David N. Neubauer, MD Associate Professor, Johns Hopkins University Murray B. Stein, MD, MPH Professor of Psychiatry and Family and School of Medicine, Baltimore, MD Preventive Medicine, University of California San Diego, La Jolla, CA; StaffSteven A. King, MD, MS Clinical Professor of Psychiatry, New York Psychiatrist, VA San Diego Healthcare System, La Jolla, CAUniversity School of Medicine, New York, NY Douglas L. Noordsy, MD Associate Professor of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH; Associate Editor, Journal of Dual Michael E. Thase, MD Professor of Psychiatry, Perelman School of MedicineKurt Kroenke, MD Professor of Medicine; Indiana University School of of the University of Pennsylvania, Philadelphia, PA; Staff Psychiatrist, DiagnosisMedicine; Indianapolis, IN Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Adjunct George I. Papakostas, MD Director, Treatment-Resistant Depression Professor of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PAStephen B. Levine, MD Co-Director, Center for Marital and Sexual Studies, Massachusetts General Hospital, Boston, MA; Associate ProfessorHealth, Beachwood, OH; Clinical Professor of Psychiatry, Case Western Matthew Tierney, NP, MSN Director, Office-Based Buprenorphine of Psychiatry, Harvard Medical School, Boston, MAReserve School of Medicine, Cleveland, OH Induction Clinic, San Francisco General Hospital, Department of Psychiatry, Anton P. Porsteinsson, MD William B. and Sheila Konar Professor, San Francisco, CA; Assistant Clinical Faculty, University of California, SanLorin Lindner, PhD Clinical Psychologist, Private Practice, Frazier Park, University of Rochester School of Medicine and Dentistry, Rochester, NY Francisco, School of Nursing, San Francisco, CAValencia, Bakersfield, Beverly Hills, CA Sheldon H. Preskorn, MD Professor of Psychiatry, University of Kansas Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial ProfessorWilliam Lopez, MD Lead Medical Director, Acute Behavioral Regional School of Medicine, Wichita, KS; Chief Science Officer, Kansas University and Vice Chair, Department of Psychiatry, The University of Texas MedicalTeam, Cigna Healthcare, Eden Prairie, MN Clinical Trial Unit, Wichita, KS Branch, Galveston, TX; Director, Division of Child and Adolescent PsychiatryStuart L. Lustig, MD, MPH Medical Director, Cigna Healthcare, Glendale, Alya Reeve, MD, MPH rincipal Investigator, Continuum of Care, P Sara Waller, PhD Associate Professor, Philosophy, Montana StateCA; Adjunct Associate Professor, Department Psychiatry, University of University of New Mexico, Albuquerque, NM; Associate Professor, University, Bozeman, MTCalifornia San Francisco, San Francisco, CA Psychiatry, Neurology, and Pediatrics, University of New Mexico,Oren Mason, MD Founder and Director, Attention MD, Grand Rapids, MI; Albuquerque, NM Tonia L. Werner, MD Assistant Professor and Chief of Forensic Psychiatry,Assistant Professor, Michigan State College of Human Medicine, Grand Rapids, MI University of Florida, Gainesville, FL Phillip J. Resnick, MD Professor of Psychiatry, Case Western Reserve University, Cleveland, OH Paul Zarkowski, MD Clinical Assistant Professor, University of Washington, Seattle, WARegister Today: call 800-237-7285, ext. 233 Register early and save 5
  6. 6. ® ® Scientific Program SCIENTIFIC PROGRAM Thursday, november 8, 2012 THURSDAY, NOVEMBER 8, 2012 Attacking Anxiety Disorders 2012 Scientific 8:30 a.m.–10:00 a.m. Anxiety disorders are among the most prevalent mental disorders seen in the community, primary care, and psychiatry specialty prac- Program Overview tice. Anxiety disorders are often comorbid with major depression, Facilitating Systems Change in Schizophrenia Manage- substance use disorders and, frequently, other medical disorders. *as of August 9, 2012; sessions and schedule subject to change without notice. ment: A Dual Curriculum for Mental Health Care Profes- This session provides an update on the pharmacotherapeutic sionals and Managed Care to Align Treatment Strategies management of several of the most common anxiety disorders. The 2012 Psych Congress Scientific Program with HEDIS Measures If relevant, differential pharmacotherapy of these disorders will focuses on sessions that provide knowledge and The goal of this activity is to address barriers to the effective be discussed, including expectations for responses when treat- tools from which mental health care professionals management of schizophrenia, as well as to discuss managed care ing patients with certain comorbid conditions. The session also strategies to better enable mental health care professionals to discusses cognitive-behavioral therapeutic and measurement-based may confidently diagnose disorders and develop improve patient outcomes and quality of life. care approaches that can be implemented within the context of a effective individualized treatment plans to achieve Track(s): TBA predominantly psychopharmacotherapeutically oriented practice to patient wellness by applying evidence-based man- Speaker(s): TBA improve patient outcomes. This activity is supported by an educational grant from Janssen, Di- Track: Anxiety Disorders agement into daily practice. The program covers a vision of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered Speaker: Murray Stein, MD, MPH broad spectrum of topics and educational formats, by Ortho-McNeil Janssen Scientific Affairs, LLC. providing more than 80 sessions to choose from. Social Security Disability for Psychiatry Cancer and Behavioral Disturbances: As patients apply for Social Security disability in ever-higher num- Mind-Body Perspectives bers, treating mental health care professionals must have an un- This session brings understandings from mind-body science to bear derstanding as to what is expected of them as treatment sources. on the complex relationships that pertain between cancer and a This session covers the specific disability policies and guidelines variety of behavioral disturbances, including depression, anxiety, utilized by the Social Security Administration. It also covers criteria and fatigue. Adopting a perspective that sees psychological, to be used by physicians serving as consulting evaluators for state social, and immune processes as inextricably linked provides novel Social Security offices as well as for those serving, or interested in insights into the pathophysiology and treatment of depression, serving, as medical experts at the federal level. anxiety, and fatigue that occur in the context of cancer and/or its Tracks: Practice Management, Forensic Psychiatry treatment. This session explores the pragmatic treatment implica- Speaker: Stuart Gitlow, MD, MPH, MBA tions of these insights. Tracks: Cancer Psychiatry, Mood Disorders Speaker: Charles Raison, MD6 Register Today: Register early and save
  7. 7. Scientific Program Thursday, november 8, 2012 ® ® MDMA-Assisted Psychotherapy for Posttraumatic Stress10:15 a.m.–11:45 a.m. Disorder: Recent and Current Research into a Promising New TreatmentADHD Across the Lifespan: Research into MDMA-assisted psychotherapy is a relatively recentDiagnostic and Treatment Considerations area of investigation that is growing quite rapidly, and about whichAttention-deficit/hyperactivity disorder (ADHD) is a disorder in there has been considerable media attention but few papers in thewhich symptoms evolve over time, necessitating a wider develop- medical literature. The first completed controlled trial of MDMA-as-mental perspective when diagnosing, recognizing comorbid condi- sisted psychotherapy was published in the Journal of Psychophar-tions, and treating ADHD across age groups. This session presents macology in 2010. This session presents the history of MDMA as athe implications of ADHD across the lifespan and differences in possible therapeutic agent and current research around the worldclinical presentation, functional impairments, and diagnostic strate- on MDMA-assisted psychotherapy for posttraumatic stress disorder.gies. The session reviews practical approaches to diagnosis, includ- Track: Posttraumatic Stress Disordering using developmentally appropriate rating scales and treatment Speaker: Michael Mithoefer, MDstrategies in light of commonly occurring comorbidities.Track: ADHD Addictive Disease: A Practical GuideSpeaker: Craig Donnelly, MD Even those who think of addiction as a chronic life-threatening dis- ease often categorize it separately from other similar illnesses, suchA Fun, Powerful Technique for Teaching Children as hypertension and diabetes. This session focuses on a method ofHow to Stop Being Bullied considering the three building blocks of addictive disease: genetic,The problem of bullying has become of increasing concern as more environmental, and sociologic. This will help attendees regard ad-and more children take their lives because they cannot tolerate diction as one would consider other, similar medical conditions.being bullied. Unfortunately, mental health care professionals are Track: Substance Abuse, Addiction and Deterrenceoften at a loss for how to help victims of bullying, because the Speaker: Stuart Gitlow, MD, MPH, MBAorthodox approach to the problem requires them to serve as policeofficers, protecting children from each other instead of equipping Treating the Whole Patient: Examining Receptors in De-them to solve their problem. This workshop provides a simple and pression: Enhancing Opportunities and Minimizing Risk TWPfun approach to quickly teach victims of bullying the knowledge This session on depression will examine the latestand skills to stop being bullied. information on the role of receptors in the regulation of mood 12:00 p.m.–1:30 p.m.Tracks: Child and Adolescent Psychiatry, Psychotherapy and the genesis of depression, and translate this deep knowledgeSpeakers: Doris Greenberg, MD; Israel Kalman, MS, MD into an understanding of the roles different receptor agonists and Professional Medical Education Presentation antagonists play in the treating depression to improve patient care Topic: Schizophrenia and treatment outcomes. Lunch will be served. Tracks: Mood Disorders, Wellness This presentation is provided by Sunovion Pharmacueticals, Inc. Speakers: Jon W. Draud, MS, MD; Rakesh Jain, MD, MPHRegister TodaY: call 800-237-7285, ext. 233 Register early and save 7
  8. 8. ® ® Scientific Program Thursday, november 8, 2012 Time for a Psychiatric Gut Check: The HPA-Gut Axis and Physician Well-Being: Who Cares? Mood Symtpoms Mental health care professionals are experiencing an ever- The goal of this session is to provide health care professionals with the increasing barrage of responsibilities and expectations. This session tools required to identify patients with depression and other psychiatric explores mental health care professionals’ apparent lack of concern illnesses, who possess features that suggest cytokine sensitivity (inflam- for their own well-being as they strive to maintain that of their pa- mation) emanating from the the gastrointestinal system. Such tools will tients. It also identifies stresses and situations that provoke stress, help health care professionals enhance and expand their repertoires of while offering potential approaches to their management. treatment and management options, thereby yielding improved patient Track: Wellness care, clinical outcomes, and general wellness. Speaker: Gregory Franchini, MD Track: Mood Disorders Speaker: David Scheiderer, MD, MBA, DFAPA Understanding and Managing Traumatic Stress This session provides an overview of the epidemiology of posttrau- Update on Treatment of Bipolar Disorder matic stress disorder (PTSD), emphasizing recent studies in the mili- in Children and Adolescents tary. It links these data pointing to a profound need for treatment This session provides mental health care professionals with with an evidence-based update on treating acute stress disorder new information about treatments for bipolar disorder (BD) in and PTSD, and highlights pharmacotherapeutic approaches. children and adolescents. The relative benefits and risks of atypical Track: Posttraumatic Stress Disorder antipsychotics, mood stabilizers, and alternative therapies will be Speaker: Murray Stein, MD, MPH discussed to improve mental health care professionals’ treatment strategies for BD in children and adolescents. Optimizing the Managed Care Doc to Doc: Tracks: Mood Disorders, Child and Adolescent Psychiatry New Strategies That Work, from the Perspective of Man- Speaker: Karen Dineen Wagner, MD, PhD aged Care’s Peer Reviewers 12:00 p.m.–2:00 p.m. The goal of this panel-led presentation is to present inpatient 2:15 p.m.–3:45 p.m. clinicians who do managed care peer reviews on behalf of their New and Emerging Multi-target Approaches for the Treat- patients with a deeper understanding of how to better advocate ment of Major Depressive Disorder Spice, Bath Salts, and Salvia: Understanding for their patients within the framework of typical level-of-care The goal of this initiative is to provide mental health care profes- Emerging Drugs of Abuse guidelines. Presenters, both of whom are medical directors con- sionals with knowledge on new and emerging multi-target agents Substances of abuse often evolve faster than clinical or legal ducting peer reviews for a health care company, will discuss tactics for the treatment of major depressive disorder (MDD), as well as systems. This session examines three emerging drugs that can that will make clinicians in inpatient settings more savvy case strategies for individualizing treatment and improving adherence be abused: synthetic cannabinoids (spice), synthetic cathinone presenters who can move beyond the admission or continued-stay among patients with MDD. stimulants (bath salts), and the naturally occurring hallucinogen criteria about dangerousness to self or others in order to optimize Track: Mood Disorders Salvia divinorum. Discussions include the epidemiology, risks, and clinical care. Speakers: Gustavo Alva, MD, DFAPA; Vladimir Maletic, MD, MS potential therapeutic uses of these drugs. Tracks: Assessment and Adherence, Practice Management This session is supported by an educational grant from Takeda Track: Substance Abuse, Addiction and Deterrence Speakers: Stuart L. Lustig, MD, MPH; William Lopez, MD Pharmaceuticals Inc. Speaker: Andrew Penn, RN, MS, NP, CNS8 Register Today: Register early and save
  9. 9. Scientific Program Thursday, november 8, 2012 ® ®Treating the Whole Patient Expert Course: Expert emphasizes consensus clinical guidelines. Promoting good sleep Brief, Brief, Brief! Scientific Breakthroughs and Clinical Ap-Examination of Critical Issues in Receptor-Based TWP habits and treating sleep disorders will be emphasized as impor- plications of Ultra Short Meditation TrainingPharmacology in Depression tant components to wellness. Meditation practices are centuries old and the benefits documented,These engaging, small-group discussions aim to integrate Track: Sleep Disorders but use in clinical settings is quite low. Meditation practices are oftenscientific advances and theoretical knowledge into best clinical Speaker: David Neubauer, MD associated with long, uncomfortable periods of sitting, searching forpractice to achieve the optimal balance between treatment nirvana. This session offers another option: brief meditation, as littleefficacy and potential risks, while promoting therapeutic Bipolar Disorder in Women as one hour of training and practice. Discussions include scientific andcollaboration, treatment adherence, and wellness practices. This session summarizes clinically relevant research about practical information on its benefits.The intimate learning environment encourages engagement gender differences in bipolar disorder (BD) and the influences of Track: Psychotherapyon possible diagnostic, treatment and management strategies reproductive-cycle events on BD in women. Discussions include a Speaker: Saundra Jain, MA, PsyD, LPCusing case examples. Enrollment is limited and pre-registration review of pharmacologic considerations unique to women, such asis required for all Expert Courses. dosing strategies across the menstrual cycle and prescribing mood- 5:45 p.m.–7:15 p.m.Tracks: Mood Disorders, Wellness stabilizing agents during pregnancy and lactation, and applicationsSpeakers: Jon W. Draud, MS, MD; Rakesh Jain, MD, MPH of interpersonal and social rhythm therapy, family-focused therapy, To Test or Not to Test: The Use of Biological Markers and*Pre-registration is required for this session. and cognitive-behavioral therapy to women with BD at different Laboratory-Based Testing in Clinical Psychiatric Practice reproductive stages. The goal of this session is to provide health care professionals the4:00 p.m.–5:30 p.m. Track: Women’s Mental Health tactics needed to identify and employ currently available tests de- Speaker: Laura Miller, MD signed to expand our treatment options with the aim of improvingPreventing Cognitive Decline in Your Patients patient care, clinical outcomes, and general health.Alzheimer’s disease and other dementias have become major Evidence Update for A Novel Model for Understanding Track: Assessment and Adherencehealth concerns in aging societies, making early identification of at- and Treating Autism Speaker: David Scheiderer, MD, MBA, DFAPArisk subjects of utmost importance. To be discussed: biomarker and Recent research about the etiology of autism spectrum disordersdiagnostic technologies and possible interventions for preventing (ASD) suggests novel models and mechanisms may affect ASD as- Management of Treatment-Resistant Depression incognitive decline in middle-aged and elderly patients. sessment and treatment. What we know has grown exponentially Children and AdolescentsTrack: Dementia and Cognitive Disorders over the past two years. This session aims to provide an update and This session provides mental health care professionals with clini-Anton Porsteinsson, MD increase consideration of these novel mechanisms in their research cally relevant information about strategies to manage treatment- and integrative practices. It also introduces a new paradigm for resistant depression in children and adolescents. AugmentationImplementing Effective Insomnia Management: understanding the neurodevelopmental, gene X-environment inter- with other medications, psychotherapy, and alternative treatmentImportant Issues in Evaluation and Treatment action in the etiology and uses this to define treatment targets. modalities are among the methods to improve responses in youthInsomnia is prevalence in the general population and quite com- Tracks: Autism Spectrum/Developmental Disorders, Neurology/ who fail to respond to initial treatment with an antidepressant.mon among people with mental health disorders. This session Neuroscience Tracks: Mood Disorders, Child and Adolescent Psychiatryreviews diagnosing insomnia; highlights common challenges in Speaker: Robert Hendren, DO Speaker: Karen Dineen Wagner, MD, PhDevaluating patients with sleep disturbances; considers key advan-tages and disadvantages of the major treatment options, includingcognitive-behavioral and pharmacotherapeutic approaches; andRegister Today: call 800-237-7285, ext. 233 Register early and save 9
  10. 10. ® ® Scientific Program Friday, november 9, 2012 FRIDAY, NOVEMBER 9, 2012 Anger Control Made Easy People get angry because they feel abused by others. The truth is 8:00 a.m.–9:30 a.m. usually the other way around: people continue to get abused because they are getting angry. This workshop demonstrates a quick and Professional Medical Education Presentation powerful method for teaching patients to solve relationship problems Topic: Major Depressive Disorder and stop being abused by controlling their anger. Breakfast will be served. Tracks: Abuse/Trauma, Psychotherapy This presentation is provided by Mylan, Inc. Speakers: Doris Greenberg, MD; Israel Kalman, MS, MD 8:00 a.m.–10:00 a.m. Using the Neurodevelopmental Formulation in Clinical Practice Evidence-Based Pharmacologic Strategies for Partial or Non- Although our understanding of mental disorders is shifting through response to Treatment in Major Depressive Disorder neuroscience research, a clinically useful neurodevelopmental model Ethics and Evidence-Based Psychiatry The goal of this activity is to present guideline-concordant approaches has not been established for assessment and treatment planning. The Mental health care professionals are often unfamiliar with standard to the pharmacologic management of partially responsive and goal of this session will be to discuss a neurodevelopmental model principles of ethics and how they apply to their field. This session ex- treatment-resistant depression, with the ultimate goal of achieving developed based on new research as it relates to mental disorders plores the ethical implications of practicing evidence-based Psychiatry. sustained remission in patients with major depressive disorder. that emerge in childhood and adolescence, with a particular focus This session explains what evidence-based medicine means in mental Track: Mood Disorders on schizophrenia, affective disorders, autism and attention-deficit/ health care, and the ways in which this paradigm is and is not ap- Speakers: Bradley Gaynes, MD, MPH; Joseph Goldberg, MD; hyperactivity disorder. This session aims to provide a practical, state- propriate for diagnosing and treating psychiatric patients. Sanjay Johan Mathew, MD of-the-art, understanding of etiology and treatment planning. Gene Track: Ethics This session is supported by an educational grant from Otsuka America sequencing, imaging, epigenetics, relating animal models to humans, Speaker: M. Carmela Epright, PhD Pharmaceutical. commonalities and biomarkers guiding treatment, and targeted treat- ments across disorders will be emphasized. Management of Transgendered Patients 8:30 a.m.–10:00 a.m. Tracks: Neurology/Neuroscience, Child and Adolescent Psychiatry Through the Lifecycle Speaker: Robert Hendren, DO The media glamorize the treatment of gender identity disorder, which New Approach to ADHD Medication — tends to distort the ordinary clinical realities and comorbidities of these Combination Therapy The Modern Treatment of Erectile Dysfunction: patients. This session provides a balanced perspective on interventions Combination therapy has been used informally in mental health Organic and Psychogenic for transgender problems as they present in childhood, adolescent, care, but new evidence is emerging that combination therapy is safe Psychiatric patients have at least as much erectile dysfunction (ED) and early, middle and late adulthood. Discussions include defining and effective for difficult and treatment-resistant cases of attention- as the general population (increases with age), but their physi- the erotic and sexual components of sexual identity and acquainting deficit/hyperactivity disorder (ADHD). This session presents research cians generally do not focus on the topic. This session provides the participants with the clinical and political controversies embedded in review and multiple case histories that will demonstrate a variety of evidence-based data and the attitudes required to improve the somatic, psychotherapeutic, and advocacy interventions. approaches to combination therapy in ADHD. Discussions include assessment and effective treatment of ED. Track: Sexual Disorders practical methods to optimize efficacy and improve tolerability. Tracks: Sexual Disorders, Psychotherapy Speaker: Stephen Levine, MD Track: ADHD Speaker: Stephen Levine, MD Speaker: Oren Mason, MD10 Register Today: Register early and save
  11. 11. Scientific Program Friday, november 9, 2012 ® ®10:15 a.m.–11:45 a.m. The X Factor (Alprazolam): Friend or Foe? Professional Medical Education Presentation Alprazolam is in the news everywhere. The recent deaths of mul- Topic: SchizophreniaAssessment and Mangement of Major Depressive Disorder tiple celebrities involving alprazolam misuse are stark testimony Lunch will be served.Emerging evidence suggests that several clinical factors may be to this deadly problem, yet countless clinicians and patients report This presentation is provided by Sunovion Pharmaceuticals, Inc.relevant with regard to predicting the likelihood of responding to benefit from this medication. What are we clinicians to make ofstandard antidepressant therapy (predictors), as well as in defining this? Is alprazolam a friend or foe? This session offers both sidessub-populations of patients whose depression may preferentially of this challenging story so that we clinicians can individually 12:30 p.m.–2:00 p.m.respond to one given treatment over another (moderators of treatment make up our minds about the potential benefits and the pitfalls ofoutcome). Ultimately, being able to select an appropriate treatment using this controversial medication. Schizophrenia: The Role of Symptom Domainsbased on clinical presentation or the presence of biologic markers may Track: Anxiety Disorders on Patient Outcomeshelp improve the standard of care for major depressive disorder. The Speakers: Rakesh Jain, MD, MPH; Saundra Jain, MA, PsyD, LPC The goal of this initiative is to improve the competence andgoal of this session is to review a standard approach for evaluating a confidence of mental health professionals in identifying the primarypatient with a major depressive episode, followed by a conceptual ap- Broadening Horizons: A Focus on Current and Emerging and secondary symptom domains of schizophrenia while address-proach to first-line treatment selection with an emphasis on identifying Therapies in Schizophrenia ing them more effectively with existing and novel treatments tocommon pitfalls of contemporary antidepressant therapy. The goal of this activity is to give mental health care professionals optimize outcomes for patients.Track: Mood Disorders a better understanding of the benefits and limitations of currently Track: SchizophreniaSpeaker: George Papakostas, MD available antipsychotic agents and knowledge of emerging schizo- Speakers: Henry Nasrallah, MD; Joseph McEvoy, MD phrenia treatments. This session is supported by an educational grant from Genentech, Inc.Traumatic Stress Psychotherapy Using an Track: SchizophreniaIntegrated Approach Speakers: Christoph U. Correll, MD; Diana Perkins, MD, MPH Introduction to Neuroethics for CliniciansAlthough recent trends in posttraumatic stress disorder treatment This session is supported by an educational grant This session explores multidisciplinary implications of the rap-focus on a handful of manualized interventions, an integrated from Lilly USA, LLC. idly advancing field of neuroscience. Participants will considerpsychotherapy approach to counseling trauma survivors may be a range of ethical, moral, and medical issues associated witha more appropriate approach, given the varying and unique emo- Exhibit Hall and Education Annex neuroscience research including how these studies informtional needs of each trauma survivor. Conceptualizing traumatic an understanding of autonomous selves, notions of free will, 11:00 a.m.– 4:00 p.mevent response as also including multiple levels of loss may provide and conceptions of legal and moral responsibility. Discussionsmental health providers with a model in which to strategically include applications to psychiatric treatment, personal enhance-address these various needs. The goal of this session is to discuss 12:00 p.m.–1:30 p.m. ment, and social, economic and political objectives.the benefits of using multiple theories and interventions in order Track: Ethicsto avail client-centered, emotion-focused psychotherapy — from Professional Medical Education Presentation Speaker: M. Carmela Epright, PhD; Judith Grisel, PhD;which cognitive and emotional processing of traumatic memories Topic: Depressive Disorders Sara Waller, PhDcan occur, toward the outcome of relieving long-standing stuck Lunch will be served.cognitions and emotions. This presentation is provided by Takeda Pharmacueticals, Inc.Tracks: Posttraumatic Stress Disorder, PsychotherapySpeaker: Lori Daniels, PhDRegister Today: call 800-237-7285, ext. 233 Register early and save 11
  12. 12. ® ® Scientific Program Friday, november 9, 2012 Cannabis and Mental Health: Risks and Research Unopposed Exhibit Hall and Divorce: The Effects on Children and How to Marijuana is a commonly used drug in the United States and pres- Education Annex Help Lessen the Trauma ents risks for serious mental health problems. This session describes Millions of children suffer the after-effects of divorce. Courts often the effects of marijuana and the dangers posed to mental health, 2:00 p.m.– 4:00 p.m impose unworkable visitation and other hardships on the parents as well as the body’s endogenous cannabinoid system and how it and children. This session discusses the effects of divorce on chil- is being researched to develop medications that may treat mental 4:00 p.m.–5:30 p.m. dren and adolescents, how to advise families and courts, and how health problems. to assist the children when their families are fractured. Tracks: Substance Abuse, Addiction and Deterrence, Personalized Approaches to Treating Depression: Tracks: Child and Adolescent Psychiatry, Forensic Psychiatry Neuromodulation Folate-Based Therapies Speaker: Doris Greenberg, MD Speaker: Matthew Tierney, NP, MSN The goal of this activity is to provide mental health care profes- sionals with an increased awareness and understanding of Targeting Glutamate in the Quest to Develop Novel Faith, Fundamentalism, and Frontal Lobe Function augmentation/combination strategies with folate-based thera- Treatments for Mood Disorders Recent high-profile forensic cases involving defendants who pies when developing individual treatment plans to improve The monoaminergic hypothesis of mood disorder pathophysiology espouse conspiracy-based religious or political beliefs, or whose outcomes of patients with MDD. has dominated the field for five decades. This session presents thinking is dominated by extreme fundamentalist religious ideas, Track(s): TBA the basic neurobiological and pharmacological foundations of the have created complex and confusing challenges for U.S. courts and Speaker(s): TBA novel class of glutamatergic drugs that are under investigation for the psychiatric experts who attempt to assist them. This session This activity is supported by an educational grant from Pamlab, LLC. the treatment of mood disorders. clarifies the purpose of laws that provide accommodation for Tracks: Mood Disorders, Neurology/Neuroscience individuals with severe mental diseases or defects and the nature Preconception Planning for Women with Speaker: Gerard Sanacora, MD, PhD of the validity problems with the current DSM/empiric system of Psychiatric Disorders diagnosis. It provides a neuroscience-based model for accurately This workshop addresses the clinical complexities of planning a Multiple Medication Use: Why, How and So What? identifying the Axis I, Axis II, and cultural components of mental pregnancy in the context of a pre-existing psychiatric disorder This presentation will review the extent of multiple medication and behavioral function (or dysfunction) in these defendants as or risk factors for perinatal psychiatric complications. Using a use, why and how it occurs, what the potential clinical outcomes well as other complex clinical cases. Finally, this session provides an case-based interactive format, the workshop explores strategies are, and what clinicians can do manage this issue to optimize empiric, three-domain model for conceptualizing religion, as well for reducing perinatal and long-term risks to women and their patient outcomes. as a developmental model for distinguishing healthy and unhealthy offspring of both untreated mental illness and of pharmacologic Track: Psychopharmacology forms of religious experience, and guidelines for optimal therapeu- treatments. Discussions include ways to modify psychopharmaco- Speaker: Sheldon Preskorn, MD tic engagement with the religiously committed patient. logic regimens and optimize non-pharmacologic interventions. Tracks: Forensic Psychiatry, Neurology/Neuroscience Wellness Track: Women’s Mental Health Speaker: Noel Gardner, MD, MDiv Speaker: Laura Miller, MD MEET THE EXPERTS 2:00 p.m–2:30 p.m, 2:45 p.m–3:15 p.m, and 3:30 p.m–4:00 p.m12 Register Today: Register early and save
  13. 13. Scientific Program Friday, november 9, 2012 ® ®5:45 p.m.–7:15 p.m. Continuing Education Credit CME LLC is accredited by the Accreditation Council for Continuing Medical Education toADHD Medication Close-Up: provide continuing medical education for physicians.Angels and Devils in the Details CME LLC designates this live activity for a maximum of 30 AMA PRA Category 1Medication management for patients with attention-deficit/ Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.hyperactivity disorder (ADHD) requires careful attention to issues Provider approved by the California Board of Registered Nursing, Provider Numberof efficacy and tolerability. Small differences between similar CEP12748 for 30 contact hours.medications can often make large differences in clinical response. CME LLC is approved by the American Psychological Association to sponsor continuing edu- cation for psychologists. CME LLC maintains responsibility for this program and its content.A multimedia tour of the first-line medications for ADHD will famil- Physician assistants, nurse practitioners, and nurses may participate in this educationaliarize participants in the details that lead to successful treatment activity and earn a certificate of completion, as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.of ADHD. Other health care professionals should check with their state licensing and certificationTracks: ADHD, Assessment and Adherence boards to determine if Psych Congress meets their continuing education requirements.Speaker: Oren Mason, MD Requirements for Credit To be eligible for documentation of credit for each session attended, each participant mustIs Happiness Teachable? participate in the full activity and complete the online general survey and the online evalua-Positive Psychology in Everyday Clinical Practice tion form for each session.Is happiness something a person can learn? Is it a choice, or are Disclosureyou born with a certain, unchangeable amount? Is this just pop It is the policy of CME LLC to ensure balance, independence, objectivity and scientific vigor in all sponsored or jointly sponsored educational activities. Any individual in a position topsychology, or does it have a place in our modern treatment ap- control the content of an educational activity, including course or activity directors, advisoryproaches? This session reviews data from the school of positive try. This session focuses on clinically relevant, evidenced-based board members, staff, teachers or authors of CME, must disclose all relevant financial relationships and the nature thereof that they or any member of their family have withpsychology, which stresses that happiness is something we can treatment of BD-II. commercial interest(s). The ACCME describes relevant financial relationships as those in any amount occurring within the past 12 months that create a conflict of interest. Individualslearn and can teach our patients. The session also offers practical Track: Mood Disorders who refuse to disclose will be disqualified from participation in the development, manage-tips on how to incorporate positive psychology into everyday Speaker: Stephen Sobel, MD ment, presentation or evaluation of the CME activity.clinical practice. Terms and ConditionSTrack: Wellness Management of Cancer Pain All information regarding sessions, symposia, speakers, topics, events, dates, and times isSpeaker: Saundra Jain, MA, PsyD, LPC Pain is frequently experienced by patients with cancer. In addition preliminary and subject to change up to and during the 2012 Psych Congress. The total credits that will be available are not guaranteed and subject to change as circumstances to the direct suffering pain can cause, if not properly treated, it require. Attendees are responsible for checking with their state licensing and certification boards to determine if the 2012 Psych Congress meets their continuing educationThe Keys to Recognizing and Effectively Treating can result in other problems, such as hopelessness and depres- requirements. All updated information will be reflected at as itBipolar II Disorder sion, which mental health care professionals may be asked to becomes available. The meeting organizer is not liable for any travel-related penalties, fees, losses, forfeitures, or related damages in the event the meeting is rescheduled or canceled.Bipolar II disorder (BD-II) presents significant challenges to pa- address. This session discusses the different types of pain associ-tients, mental health care professionals, and medical treatment ated with cancer, how cancer pain affects the mental health of Copyright Statementprofessionals. Treatment is complicated with ever changing treat- patients, and pharmacologic and non-pharmacologic treatment Copyright © 2012 by CME LLC, a subsidiary of NACCME, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any formment needs and goals, and differs from the treatment of BD-I in strategies to relieve pain in these patients. or by any means, electronic or mechanical, without first obtaining permission from CME LLC.important ways. The role of antidepressants in the treatment of Tracks: Cancer Psychiatry, Pain I NFORMATION CONTAINED HEREIN IS SUBJECT TO CHANGE WITHOUT NOTICE.BD has become one of the most controversial topics in psychia- Speaker: Steven King, MD, MSRegister Today: call 800-237-7285, ext. 233 Register early and save 13
  14. 14. ® ® SCIENTIFIC PROGRAM Saturday, november 10, 2012 SATURDAY, NOVEMBER 10, 2012 The Child Who Isn’t Talking: Sorting Out the Causes Alzheimer’s Disease Update 2012: Since the development of speech and language heralding future The State of the Science 8:30 a.m.–11:30 a.m. academic and social competency, it is important to sort out the Alzheimer’s disease remains the third most deadly and costly reasons for a child who fails to speak on time or a child who disease in our country, exacting a staggering and growing toll Individualizing Treatment in MDD: The Role of MAOIs* speaks in certain restricted environments. This session discusses on more than 5 million Americans and an even greater number The goal of this initiative is to provide mental health care profes- the most common reasons for language and speech problems: of caregivers. Several new developments include amyloid-based sionals with an increased awareness and understanding of the autism, selective mutism, hearing problems, performance neuroimaging and the use of immunologic treatments. This ses- role of monoamine oxidase inhibitors (MAOIs) in major depres- anxiety, speech apraxia, articulation disorders, developmental sion reviews the latest developments in diagnosis and treatment, sive disorder (MDD) to be better equipped to provide individual- delays, and language problems faced by children who must including a review of all existing experimental therapies. ized care and improve patient outcomes. adjust to a new language. Discussions include selective mutism, Tracks: Dementia and Cognitive Disorders, Geriatric Psychiatry Tracks: Mood Disorders, Psychopharmacology a problem that occurs in extremely shy children and can be a Speaker: Marc Agronin, MD Speakers: George Papakostas, MD (Program Chair); Jon W. barrier between student and teacher. Draud, MS, MD; Marlene Freeman, MD; Gerard Sanacora, MD, PhD; Tracks: Child and Adolescent Psychiatry, Autism Spectrum/De- Exhibit Hall and Education Annex Michael Thase, MD velopmental Disorders 11:00 a.m.– 4:00 p.m. This activty is supported by an educational grant from Mylan Speaker: Doris Greenberg, MD Specialty L.P. *Pre-registration is required for this session. Utility of PHQ-9 and Other Brief Psychiatric 10:15 a.m.–11:45 a.m. Scales in Clinical Practice 8:30 a.m.–10:00 a.m. Measurement-based care for depression and other psychiatric Measurement-Based Care: Can the Use of Scales and disorders is being advocated and, in some cases, required by Structured Interviews Change the Course of Treatment? Meeting the Challenges of Treating People with TBI or I/ payers, quality improvement initiatives, and health care profes- Validated rating scales and structured diagnostic interviews are DD: Strategies for Assessment, Management, and Psycho- sional organizations. Valid brief self-report scales are a practical commonly used in research to aid in the diagnosis and assessment pharmacology means of assessing symptom severity of depression and other of severity of psychiatric disorders and to provide a framework for The are insufficient practitioners trained in working with people common psychiatric disorders and monitoring response to measuring response and remission. Despite this, their integration with traumatic brain injury (TBI) and intellectual and/or develop- treatment. This session discusses the practical use of scales and into clinical practice is variable even though there are benefits to mental disability (I/DD) who have concurrent mental illnesses. This screeners, such as the PHQ-9 and several brief measures for such measurement-based care. This session demonstrates how session introduces the principles for approaching patients who anxiety, somatization, and other common psychiatric disorders. rating scales and structured diagnostic interviews can be effectively present in atypical fashion, including neurologic difficulties, com- Tracks: Mood Disorders, Anxiety Disorders used to assess and monitor treatment outcomes in depression, as munication challenges, and the latest in psychiatric knowledge. Speaker: Kurt Kroenke, MD well as measuring residual symptoms and domains of therapeutic Tracks: Autism Spectrum/Developmental Disorders, Posttraumatic interest. Stress Disorder Tracks: Assessment and Adherence, Mood Disorders Speaker: Alya Reeve, MD, MPH Speaker: David Sheehan, MD, MBA14 Register Today: Register early and save
  15. 15. SCIENTIFIC PROGRAM Saturday, november 10, 2012 ® ®Breaking Free: The Keys to Effective Treatment of the 12:00 p.m.–1:30 p.m. Can Antipsychotics Impact SubstanceObsessive-Compulsive Spectrum Use or Vocational Outcomes?Treating patients who suffer from obsessive-compulsive spectrum Professional Medical Education Presentation Up to half of people with schizophrenia experience substancedisorders can cause mental health care professionals tremendous Topic: Depressive Disorders use disorders, and most are unemployed, but want to work. Thisfrustration or great satisfaction. Successful treatment of obsessive- Lunch will be served. session discusses the neurobiology of schizophrenia and addic-compulsive disorders requires a complete understanding of the This presentation is provided by Forest Pharmacuetical, Inc. tion, the role antipsychotics in the treatment of schizophreniamultiple etiologies involved, the psychotherapy required, and the and comorbid substance use disorders, and pharmacologic andsophisticated use of psychotropic medications. This session focuses 12:00 p.m.–2:00 p.m. non-pharmacologic strategies to treat and manage patients’on the clinically relevant evidenced-based treatment of obsessive- schizophrenia and comorbid substance use disorders to improvecompulsive disorders and related spectrum disorders. Bipolar 1 Depression: An Evidence-Based Approach to functional outcomes.Track: Anxiety Disorders Clinical Practice Tracks: Schizophrenia, Substance Abuse, AddictionSpeaker: Stephen Sobel, MD The goal of this activity is to provide mental health professionals and Deterrence with an up-to-date clinical perspective of bipolar 1 depression, Speaker: Douglas Noordsy, MDManaging Chronic Pain in the Elderly including an evidence-based dialogue on current and emergingThere are many specific challenges in treating chronic pain in the therapies for consideration when individualizing management Dos and Don’ts of Depositionselderly that call for the skills and knowledge of mental health care plans that best optimize outcomes. Almost all mental health care professionals are likely to haveprofessionals. Assessing pain in cognitively impaired patients requires Track(s): TBA depositions taken over the courses of their careers. This sessioncareful observation of behaviors. Many mental disorders — includ- Speaker(s): TBA helps prepare mental health care professionals for their deposi-ing delirium, depression, and anxiety — can exacerbate pain and, This activity is supported by an educational grant from Sunovion tions, including learning their rights, how to answer questions,in turn, the pain and pharmacologic treatments used can cause or Pharmaceuticals, Inc. and how to avoid common pitfalls.worsen the mental disorders. This session discusses the assessment, Track: Forensic Psychiatrypharmacologic and non-pharmacologic treatment, and management 12:30 p.m.–2:00 p.m. Speaker: Phillip Resnick, MDof pain and comorbid mental disorders in elderly patients.Tracks: Pain, Geriatric Psychiatry Update on Fibromyalgia Unopposed Exhibit Hall andSpeaker: Steven King, MD, MS Fibromyalgia is a chronic pain condition with a variety of psychi- Education Annex atric comorbidities. The tremendous dysfunction that occurs in pa-Treating the Whole Patient: Schizophrenia — tients with fibromyalgia can be improved through coordinated care 2:00 p.m.– 4:00 p.m TWPCognition and Metabolic Function often involving multiple subspecialties, especially mental healthThis session on schizophrenia will identify the neurobiological corre- care professionals. This session describes the underlying patho- MEET THE EXPERTSlations inherent to schizophrenia and translate them to proper treat- physiology of fibroymyalgia and comorbid psychiatric disorders, as 2:00 p.m–2:30 p.m, 2:45 p.m–3:15 p.m,ment selections while providing ongoing monitoring of the metabolic well as the role of mental health care professionals in treating and and 3:30 p.m–4:00 p.mstatus, and advanced diagnostic strategies for negative and cognitive managing patients with fibromyalgia.symptoms to achieve optimal patient adherence and outcomes. Track: PainTracks: Schizophrenia, Wellness Speaker: Bill McCarberg, MDSpeakers: Charles Raison, MD; Vladimir Maletic, MD, MSRegister Today: call 800-237-7285, ext. 233 Register early and save 15